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ABSTRACT 
 
Cancer has become most common threat to the people all over the world in which breast 
cancer is the second most popular cancer after lung cancer. Although innumerable research 
has been done for finding a suitable therapy to this disease, no cure so far has been 
developed.  One of the main causes of breast cancer is the stabilization of number of cell 
signalling proteins generally known as ‘client proteins’ of molecular chaperones Heat shock 
protein (Hsp90).  
Hence, inhibiting Hsp90 has been considered to be an excellent therapeutic approach in 
breast as well as other cancers where the diseased or stabilized proteins directed towards 
degradation pathway and degraded by the cellular machine proteasomal degradation system. 
Number of Hsp90-inhibitors has been reported so far and they are categorized into two types 
depending on their binding site of Hsp90. Geldanamycin which is known as N-terminal 
inhibitor and Novobiocin has been shown to bind C-terminal domain of Hsp90. However 
apart from their strong binding to Hsp90, they leave other kinds of disadvantages like 
solubility, and toxicity problems. In order to overcome the demerits, various analogues have 
been developed with a better affinity and physicochemical properties. 
In our present investigation, we have developed number of hybrid inhibitor molecules using 
existing Hsp90-inhibitors to achieve a higher binding potential as well as minimal toxic 
properties. These hybrid drugs are formed by ligating two functional groups of different 
drugs using linker bonds which could be either amide, ester, ether, alkyl or hydrogen bonds.  
To impart better molecular characteristics like intermolecular force of attraction etc. various 
functional groups like alcohol, amine, amide, carboxylic acid, oxyacid group were  
integrated. Thus wide range of hybrid drugs were designed in-silico and to evaluate their 
inhibitory potential to Hsp 90, molecular docking study was performed with both N-Terminal 
and C-Terminal domain of Hsp 90. Although docking was done at multiple sites however Lys 
112 has been found to be the potential active site for hybrid drugs like H1, H2, H3, H4 and 
H5 in the N terminal domain of Hsp 90. Among them H1 was found to have the highest 
docking score of 10.116.The 2D ligand interaction analysis confirmed the involvement of 
four residues Glutamine 43, Asn 51, Leu 96, Ala 55 and Met 98  at the binding interface. 
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Later we evaluated and analysed the pharmacodynamic profile of existing drugs as well as  
hybrid drugs and  physiochemical parameters like molecular weight, solubility, blood brain 
barrier permeability, cell permeability and human absorption were also reported. It was 
observed that hybrid drugs found to have impressive pharmaceutical profile and acceptable 
pharmacological potency than existing drugs. Moreover their druggability was tested on the 
basis of Lipinski rule of five and rule of three.  
                          In summary, we concluded that our designed Hybrid (H1) was found to be 
the best Hsp 90 inhibitor among all the existing as well as designed drugs in-silico in this 
study. We also further state that H1 drug should be experimentally synthesized in the 
laboratory to evaluate its druggabillity and anti-proliferative potential in cancer to validate 
other results. 
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1. Introduction 
1.1 Breast Cancer 
Cancer is the paradigm of series of events ranging from genetic to epigentics ranging from 
unrestrained replication of carcinogenic cells , angiogenesis, non stimulative antigrowth 
signals and pro-apoptic stimuli and escape from immune surveillance. The disease of cancer 
is quite epidemic type if not checked could take wild futile form .As according to WHO 
survey it has already tolled about 7.4 death since 2004 and still is in escalation meter 
worldwide .It is estimated to reach pinnacle of 12 million deaths by 2030.So there creates the 
emergence to have certain measure which can curtail devastating slope of cancer. (Jane et al., 
2010). 
 
In the post genomic era, diseases that are frequently caused by multiple gene abnormalities 
like cancer, Alzheimer disease which cannot be treated by just recognition of single novel 
molecular targets for cancer therapeutics as they would just provide the reduced systemic 
toxicity, but simultaneously have to confront with various problems being unable to recover 
with due to their genetic plasticity, as cancer cells are having great flexibility at adapting to a 
noxious environment. 
 
Recent research reveals that in normal human body about 300-500 normal genes are mutated 
to oncogenic trait. Most of the time cancer are characterized by dysregulation of cell signaling 
pathways at multiple steps but treatment involves only single target.(Anand et al., 2008) This 
monotarget treatment involves high cost as well as lack  of effectiveness and unassurity of 
cancer therapy . But anyhow if we retrench the conventional theory of one gene one drug and 
one disease theory and embrace on multiple drugs targeting the various sites of 
carcinogenicity then we can overcome the resistance in drug discovery (Park et al., 2007). 
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1.1.1 Traditional Treatments 
 
 Treatment of cancer involves many approaches, in which the preliminary approach was 
surgical treatment involving the removal of tumour but this approach is only preferred for 
benign and early  stage cancers not for malignant cancer. Next treatment involves the use of 
radiation which kill cancer cells with high energy rays focusing on specific oncogenic target, 
but it mode of action can also involve DNA damage and thus preventing its replication of 
cancer cells from further proliferation. Another technique involves use of chemotherapy 
drugs which are toxic to the rapidly growing cells. Many of these drugs are designed to 
interfere with the synthesis of precursor molecules needed for DNA replication; they interfere 
with the ability of the cell to complete the S phase of the cell cycle. Other drugs cause 
extensive DNA damage, which stops replication. A class of drugs called spindle inhibitors 
stops cell replication early in mitosis. 
 
1.1.2 Newer Treatments 
 
Although cancer cells have lost some of the normal responses to growth factors, some cancer 
cells still require hormones for growth. Hormone therapy for cancer attempts to starve the 
cancer cells of these hormones. This is usually done with drugs that block the activity of the 
hormone, although some drugs can block synthesis of the hormone. For example, some breast 
cancer cells require estrogens for growth. Drugs that block the binding site for estrogens can 
slow the growth of these cancers. These drugs are called selective estrogen receptor 
modulators (SERMs) or anti-estrogens. Tamoxifen and Raloxifene are examples of this type 
of drug. Similarly, testosterone (an androgen hormone) stimulates some prostate cancer cells. 
Selective androgen receptor modulators (SARMs) are drugs that block the binding of 
testosterone to these cancer cells, inhibiting their growth and possibly preventing prostate 
cancer. 
Another promising target for cancer therapy is angiogenesis. Several drugs, including some 
naturally occurring compounds, have the ability to inhibit angiogenesis. Two compounds in 
this class are angiostatin and endostatin; both are derived from naturally occurring proteins. 
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A technique called chemo immunotherapy attaches chemotherapy drugs to antibodies that are 
specific for cancer cells. The antibody then delivers the drug directly to cancer cells without 
harming normal cells, reducing the toxic side effects of chemotherapy. A similar strategy, 
radio immunotherapy, couples specific antibodies to radioactive atoms, thereby targeting the 
deadly radiation specifically to cancer cells. 
 
1.2 HSP 90 and its inhibitors 
 
One of the most abundant conserved and ubiquitously expressed   molecular chaperones in 
eukaryotes (Bahls et al., 2002) this protein is in general responsible for stabilizing, maturation 
and maintenance of the conformational integrity of its 200 client proteins through its ATPase 
activity. It functions in coordinated manner with collaboration of  co chaperones like Hsp70 
and Hsp40 with its  client proteins like Her2, Raf-1, Akt, Cdk4, polo-1 kinase, B-Raf,HIF-1a, 
, Bcr-Abl ,mutant p53 which are responsible for cell  regulation and signalling.(Morgan et al., 
2014). 
Hsp90 inhibitors have more affinity as well as over expression for cancer cells then other 
somatic cells that is why it serves as more promiscuous target for anti-cancer drug 
development.(Jia et al., 2004). 
Structurally it is the constitutive protein of 732 amino acids belonging from super family of 
DNA gyrase, Histidine kinase and DNA mismatch pair. It has two isomers α and β, mainly 
present in cytosol is homodimer whose monomer consist  of four structural domains, 55 kDa 
the C-terminal (CTD) containing MEEVD motif and 25kDa N-terminal (NTD) containing 
specific ATP binding site and a middle domain (MD) connected to the NTD through an 
unstructured linker region.( Sreedher et al., 2013). Hsp90 exists in four diﬀerent isoforms 
present in eukaryotic cells and plays a central role in the complex network of cellular 
functions. Both domains are targeted to bind to substrate polypeptides, which led to 
dimerization because of change in Hsp90 conformation. At dimerization state, hsp90 alpha 
binds to ATP in its open state and thus facilitates the attachment of co-chaperones and client 
protein binding. Bur when ATP hydrolyzes Hsp90 reaches closed conformation. Thus by 
inhibiting ATPase cycle chaperoning function of Hsp 90 is altered and mutated client protein 
is subsequently addressed to proteasomal degradation pathway.( Pratt 
 
et al., 2010). 
 
 
5 
 
Most of the Hsp90 inhibitors available are from natural sources or synthetic derivatives of 
natural compounds. However, there is yet to be an approved Hsp90 inhibitor drug on the 
market. Four different mechanisms for inhibiting the function of Hsp90 are known: (1) 
competitive inhibition of ATP binding, (2) targeting and disruption of Hsp90-co-chaperone 
interactions, (3) targeting and disruption of Hsp90-client protein interactions, and (4) 
interference with post-translational modification of Hsp90 (Li et al., 2009). 
 
1.3 Computational Techniques 
 
In todays scenario computational biology and cheminformatics are devoted to large-scale 
generation and analysis of information derived from 3D structures and dynamics of proteins, 
with the goal of scientiﬁc and commercial breakthrough in drug discovery (Kelley et.al., 
2009). Rational drug design facilitates and speeds up the drug designing processes that 
involves various method of identifying novel compounds. One advanced method is the 
docking of the drug molecule or ligand or inhibitor with the target. Docking is a term used for 
computational schemes that attempt to ﬁnd the “best” matching between two molecules: a 
receptor and a ligand. Docking is used to identify and optimize drug candidates by examining 
and modelling molecular interactions between ligands and target macromolecules. 
Pharmacophore library screening is followed by docking represent complimentary screening 
methods with the combination providing optimum results. Commonly, this screening 
approach is preceded by a prior filtering of virtual databases (e.g. physicochemical, 
ADMET/PK, stability, reactivity, toxicity, drug-like properties, etc.) (Kapetanovic et al.,  
2008). 
 
 
 
 
 
 
 
 
 
1.4 Objective 
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 To design chimeric compounds by conjugation of two existing natural inhibitors. 
 
 Active site prediction of full Hsp 90 protein. 
 
 To investigate the interaction of hybrid drugs at both termini of Hsp 90 and finding the 
best fit poses. 
 
 Free binding energy estimation on the basis of MMGBSA field. 
 
 To analyze pharmacodynamic profile of each hybrid conjugates on the basis of various 
physiochemical parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
------------------------------------------------------------------------------------ 
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            CHAPTER 2 
------------------------------------------------------------------------------------ 
 
 
                    Review of Literature 
 
 
 
 
 
 
 
 
 
 
2.1 Molecular chaperones and Hsp 90  
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Althoughgaminogacid sequencegandgthe lawsgof thermodynamicsgdetermineg a protein’s 
native conformation,gthe crowded cellular environment markedly influences folding of 
nascent polypeptide chains. The total protein concentration in the cytosol of a typical 
mammalian cell is ~300 mg per ml. As a result of this macromolecular crowding, newly 
synthesized polypeptides and previously folded proteins with low stability expose 
hydrophobic surfaces, constantly risking misfolding and aggregation. Both misfolding and 
aggregation pose a substantial burden to the organism, and protein-folding defects can give 
rise to numerous human diseases. Because abnormal protein folding can lead to many 
problems in a cell, all organisms have dedicated protein assemblies that maintain proteostasis 
and mitigate the life-threatening effects of heat and other stresses on the proteome. They also 
cooperate with the ubiquitin–proteasome system, targeting terminally misfolded proteins for 
degradation, and with translocation machineries to get proteins to their proper locations. 
Many are up regulated in response to heat and are therefore termed heat shock proteins 
(Hsps). Hsp90 is one of the most conserved HSPs, present from bacteria to mammals, and is 
an essential component of the protective heat shock response. The role of Hsp90, however, 
extends well beyond stress tolerance. Hsp90 uses the energy generated by ATP binding and 
hydrolysis to fold proteins involved in signal transduction, protein trafficking, receptor 
maturation (that is, the attainment of an active conformation and intracellular nature) and 
innate and adaptive immunity. In doing so, Hsp90 interacts with more than 20 co-chaperones, 
which guide its recognition of client proteins and modulate its biochemical activities. These 
activities are closely coupled to environmental perturbations. 
 
Specifically, under normal conditions there are high levels of Hsp90 and thus an abundant 
chaperone reservoir, which buffers proteostasis against environmental stress. Under more 
extreme environmental conditions, the chaperone reservoir can be rapidly exhausted.Hsp90 is 
a large dimeric protein found in almost every compartment of eukaryotic cells. Indeed, most 
eukaryotic genomes encode multiple compartment-specific Hsp90 proteins, which arose early 
in evolution. Although structurally similar to cytosolic Hsp90, they have distinct cellular 
functions, and probably play important parts in health and disease Hsp90 is one of the most 
abundant proteins in the cytoplasm, where it constitutes 1–2% of total protein levels. (Taipale 
et al., 1999)
 
Some Hsp90 translocates to the nucleus in response to stress and other 
stimuliHsp90 alpha functions by recruiting many co-chaperones via, Cdc37, Hop, p23, Hsp70 
and Hsp40 (Li et al., 2012). The complex formation is an energy-requiring step and involves 
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sequential ATPase cycles (Richter et al., 2004). Client proteins of Hsp90 alpha are several 
kinases viz, AKT, B-Raf mutant, MET and CDK4; Transcriptional factors HIF-1A, ERA-
receptors p53 mutant regulating cell proliferation and survival and chimeric fusion proteins 
(Theodoraki et al., 2012). 
 
 
 
                   Figure 1:- Dynamics of HSP90 and its co-chaperones (Bracher et. al.,2006). 
 
 
2.2 Hsp 90 inhibitors 
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HSP 90 is so named because of its molecular weight 90-kDa. It is anticipated that this 
molecular chaperone (Hsp90) has the most specific and most cell permeable inhibitors, and 
since this chaperone is the nucleation point for protein kinase-related chaperone machinery, 
in most cases chaperone-based kinase inhibition is achieved by using Hsp90 inhibitors. 
 
2.2.1 Benzoquinone ansamysin class of inhibitors 
 
Benzoquinone ansamycin is the first successful Hsp90 inhibitor which has reached the 
clinical trial and is most studied inhibitor, other natural products of different chemical 
structure have also been shown to inhibit Hsp90 both in vitro and in vivo. The first 
benzaquinone functional group containing drug was geldanamycin which is isolated from 
Streptomyces hygroscopicus (Supko et al., 2005). Though the antitumor effects of 
geldanamycin were initially thought to be due to specific tyrosine kinase inhibition, later 
studies revealed that the antitumor potential relies on depletion of oncogenic protein kinases 
via the proteasome (Neckers et al., 2007) Structural and biochemical studies have 
demonstrated that GA is a competitive inhibitor of ATP binding to Hsp90 (Roe et. al.2003). 
Binding of GA in the N-terminal ATP pocket restrains Hsp90 in its ADP-bound 
conformation and prevents the subsequent “clamping” of Hsp90 around a client protein 
(Blagg et al., 2003) resulting in ubiquitination and proteasomal degradation of the client 
(Mimnaugh et al., 2006) Although GA exhibited potent anti-cancer activities in preclinical 
studies, it had little clinical potential mostly due to the high hepatotoxicity observed in animal 
models. As a result, GA derivatives that maintain similar anti-cancer activities but with better 
toxicological properties were synthesized, such as 17-AAG (17-allylamino-17 
desmethoxygeldanamycin; tanespimycin, KOS-953) (Workman et. al., 1995) 17-DMAG  
(17-dimethylaminoethylamino-17-demethoxygeldanamycin) (Workman et al., 1995) and IPI-
504 (17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride) several 
drawbacks of 17-AAG, including low water-solubility, instability in solution, and low oral 
bioavailability may be the major obstacle to further clinical application (McCollum et al., 
2002). 
 
 In addition to 17-AAG, other GA derivatives have been developed for clinical use as well. 
Currently 17-DMAG, a more water-soluble analogue of 17-AAG, has entered Phase I and 
Phase II clinical testing, and displayed higher oral bioavailability, lower toxicity, and 
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increased stability compared with 17-AAG (Ronnen et al., 2007). Another water-soluble 
hydroquinone hydrochloride analogue of 17-AAG is IPI-504 (Grbovic et al., 2008). IPI-504 
is in Phase I and Phase II clinical trials to evaluate its potential for treating cancer that has 
become resistant to therapy with tyrosine kinase inhibitors. 
 
2.2.2 Resorcinol class of inhibitors 
 
Radicicol is a macrocyclic antibiotic isolated from Monosporium bonorden. Because of its 
potential to reverse the malignant phenotype like geldanamycin (Ronnen et al., 2009). It was 
initially thought to be a tyrosine kinase inhibitor. However, later studies showed its role in 
Hsp90 client protein degradation [Heath et al., 2006]. Radicicol is involved in the degradation 
of NQQ1, followed by degradation of mutant p53, which is involved in the malignant 
transformation. Thus, radicicol and its derivatives also bind in the nucleotide pocket of 
Hsp90, with nearly identical biological effects as 17AAG (Grbovic et al., 2008). 
 
In past far more than 200 client proteins have been identified by using these natural products 
like geldanamycin and radicicol. But they have always been accompanied with some perils, 
though they have been evaluated in clinical trials, but these none of the 1st generation of 
Hsp90 inhibitors has circumvented their limitations in pharmacodynamics profiles. However, 
recent studies have portrayed that some new agents, 2nd generation of Hsp90 inhibitors with 
different chemical makeup from geldanamycin and radicicol, have entered clinical trials but 
still only some of them showed clinical efficacy. 
 
2.2.3 Aminocoumarin class of inhibitors 
 
The aminocoumarins novobiocin, chlorobiocin and coumermycin A1 are structurally related 
antibiotics produced by different Streptomyces strains. They are potent inhibitors of bacterial 
gyrase. Their binding sites and their mode of action differ from those of ﬂuoroquinolones 
such as ciproﬂoxacin. Novobiocin has been introduced into clinical use against 
Staphylococcus aureus infections, and S. aureus gyrase is particularly sensitive to inhibition 
by aminocoumarins, while topoisomerase IV is much less sensitive.5(Heide L.et al., 2004) 
Structurally, novobiocin and the closely related aminocoumarin clorobiocin (composed of a 
3-dimethylallyl-4-8hydroxybenzoyl moiety, a 3-amino-4,7-dihydroxycoumarin moiety (ring 
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B) substituted with a methyl group and a chlorine atom, respectively, and a substituted 
deoxysugar . The 3″-OH of the deoxysugar is esterified with a carbamoyl group in the case of 
novobiocin and with a 5-methylpyrrole-2-carboxyl moiety in the case of clorobiocin. In 
contrast to the carbamoyl group of novobiocin, the 5-methylpyrrole moiety of clorobiocin is 
able to occupy an additional hydrophobic pocket in the GyrB subunit and to displace two 
water molecules. Thereby, clorobiocin binds more effectively to the GyrB subunit than 
novobiocin. (Anderle et al., 2007 ). 
Likewise, novobiocin and other coumarin antibiotics bind to the carboxyl terminus of Hsp90 
and also disrupt its ability to chaperone client proteins. Whether either of these classes of 
natural products will produce a better alternative to 17AAG remains to be seen, but the 
possibility remains that, if the dose-limiting toxicity. (Neckers et al., 1998)  
 
2.2.4 Anthracycline class of inhibitors 
 
Anthracyclines are anticancer compounds that were originally derived from Streptomyces 
and their anti-tumor activities were established in the 1960s. Anthracyclines are red aromatic 
polyketides and occur in variety of forms due to the structural differences in the aglycone and 
the different sugar residues attached. 
Daunomycin (daunorubicin) was the first anthracycline compound to be chatacterized 
structurally and stereochemically(Cortes-Funes et al.,2005). Danorubicin is used in treating 
acute lymphoblastic and myeloblastic leukaemias Adriamycin (generic name doxorubicin) is 
a hydroxyl derivative of daunorubicin. Doxorubicin is one of the most widely used 
chemotherapeutic agents and is generally prescribed in combination with other drugs. 
Doxorubicin has a broad spectrum of activity. It is one of the most effective drugs for solid 
tumor treatment, e.g., breast cancer, small cell lung cancer and ovarian carcinoma treatments. 
Epirubicin is an epimer of doxorubicin and differs only in the orientation of the C-4 hydroxyl 
group on the sugar. Because of this slight change in the structure, epirubicin has lower 
cardiotoxicity than doxorubicin. Epirubicin is used in the treatment of gastric and breast 
cancer and is also indicated for the treatment of carcinoid, endometrial, lung, ovarian, 
esophageal and prostate cancers as well as soft tissue sarcomas. Idarubicin is an analog of 
daunorubicin. It lacks the C-4 methoxy group and this increases its lipophilicity. Idarubicin 
has improved activity as induction therapy for acute myelogenous leukaemia3(Arcamone et 
al., 2005) like any other genotoxic agent, doxorubicin has been demonstrated to induce the 
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binding of p53 to DNA. As p53ais a major player in some forms of apoptosis, it has been 
proposed that anthracyclines may exert3 ftheir cytotoxic effect via p53 mediated apoptosis 
(Brockmann et al., 1998). The side effects of anthracyclines, like any other chemotherapeutic 
agent, are linked to their cytotoxicity to non-differentiated, proliferating normal cells. 
However, the major toxicities of anthracyclines include cardiotoxicity and myelosuppression 
and these are the major limitations of these drugs. Doxorubicin can also cause severe local 
tissue necrosis. Cardiomyopathy and congestive heart failure are the two cardiotoxic side 
effects of anthracyclines. Epirubicin is less cardiotoxic than doxorubicin but may not totally 
eliminate the risk of chronic cardiotoxicity (Arcamon et al., 2001). 
2.2.5 Flavonoids class of inhibitors 
Flavonoids are part of this family & have more than 4000 varieties. They have been classified 
according to their molecular structure that consists of two benzene rings joined by a linear 
three-carbon chain and forms an oxygenated heterocycle9(C6-C3-C6) and their large number 
arises from the various combinations of multiple hydroxyl, methoxyl, and O-glycoside group 
substituents on the basic benzo--pyrone (C6-C3-C6) moiety.(Chahar et al., 1999).  
 
Derrubone is a prenylated isoflavone that was first isolated from Derris robusta in 1972 
(Hastings et al., 1972) Derrubone was originally isolated and characterized as one of a series 
of structurally related isoﬂavonoids derived from theIndian tree Derris robusta. Isolation from 
this source provided four isoﬂavones (including 1) and ﬁve 3-aryl-4-hydroxycoumarins 
related to Derrubone’s ability to inhibit Hsp90 and not Hsp70, which coassemble to form a 
competent heteroprotein complex with luciferase in reticulocyte lysate, was determined using 
puriﬁed recombinant Hsp70. Accordingly,4derrubone (Hadden et al., 2003) has been 
identiﬁed as a natural product inhibitor of the Hsp90 protein folding machinery. It inhibits 
Hsp90-dependent refolding of luciferase and antagonizes the ability of the Hsp90-speciﬁc 
inhibitor geldanamycin to disrupt complexes formed between Hsp90, Cdc37, and their client 
kinase, HRI. Furthermore, it exhibits potent antiproliferation and Her2 degradation in human 
breast cancer cell lines as well as it speciﬁcally downregulates numerous Hsp90 client 
proteins in a concentration dependent manner. The identiﬁcation of derrubone as an Hsp90 
inhibitor provides a new natural product 5scaffold upon which the development of improved 
Hsp90 inhibitors can be pursued (Hadden et al., 1997). 
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2.2.5.1   EGCG 
Catechins from green tea belong to the family of flavonoids that are powerful antioxidants 
and free iron scavengers. Many botanical flavonoids possess strong antioxidant activities in 
the cardiovascular system. Effects of green tea on cancer chemoprevention have been 
attributed to its antioxidant activities. Structure-activity relationships of tea polyphenols on 
cancer chemoprevention were also explored. The main active compounds in green tea are 
polyphenols. In this study, 10 representative tea polyphenols were selected to evaluate their 
biological activity. Based on their chemical structures, they were separated into two groups, 
phenolic acids and flavonoids, the latter of which was separated into two subgroups, the 
flavan-3-ol unit group and the galloylated catechin group ( Du et al., 2012). 
 
2.2.6 Purine based class of inhibitors:- 
 
Hsp90 contains a conserved N-terminal ATP/ADP binding pocket and nucleotide binding 
regulates the chaperone function of the protein. Earlier studies with various Hsp90 inhibitors 
showed that most of them bind directly to the N terminal ATP/ADP site, resulting in a change 
of Hsp90 conformation and a consequent interference with its chaperone function. In a recent 
development, PU3, a purine- based Hsp90 inhibitor was designed using X-ray 
crystallographic data. PU3 behaves like geldanamycin in inhibiting Hsp90 client protein 
degradation, and in possessing a robust antitumor potential. Attempts to modify and improve 
PU3 led to the development of PU24F-Cl, which binds to the N-terminus of Hsp90 with a 30-
fold higher affinity than the parent compound, PU3, thus approximating the binding affinity 
of 17AAG. PU24F-Cl was found more selective than Hsp90 inhibitors. Its water solubility is 
also an advantage over geldanamycin and 17AAG. However, PU24F-Cl may not show the 
specific intracellular accumulation typical for the more hydrophobic geldanamycin analogues 
(Sreedharet et al., 2004). 
 
2.2.7 Triterpenoid class of inhibitors 
 
Triterpenoids are ubiquitous in the plant kingdom. Recent evidences support the beneficial 
effects of naturally occurring triterpenoids against several types of human diseases, including 
various cancers. Here, we have summarized the potential of triterpenoids belonging to the 
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lupane, oleanane, ursane, and cucurbitacin groups, and their beneficial effects based on both 
laboratory and clinical investigations. Anticancer potential of triterpenoids9and their anti-
inflammatory, anti-proliferative, and pro-apoptotic effects have been discussed both in in 
vitro and in vivo models. Importantly, a large number of preclinical efficacy studies using 
chemically-induced, as well as tumor xenograft models provided evidence that both naturally 
occurring and synthetic derivatives had chemopreventive fand therapeutic effects. In this 
review, we have highlighted several studies on chemopreventive and anticancer potential of 
triterpenoids based on various preclinical animal models of colon, breast, prostate, and 
melanoma cancers (Patlolla et al., 2012). 
 
Celastrol, also called tripterine, is a quinone methide triterpenoid isolated from the Chinese 
plant Tripterygium wilfordii Hook F (TWHF), which has been used as an anti-rheumatic in 
China for many years. Celastrol can activate HSF1, induce expression of some HSPs, down-
regulate HSP90's ability in binding to ATP and disrupt the combination of HSP90 with co-
chaperone Cdc37. All these effects indicate inhibition of HSP90 activities. In agreement with 
data on the anti-tumour effects of other HSP90 inhibitors, celastrol showed similar action 
upon a variety of tumour cells. Moreover, using in silico screens of public gene expression 
data, celastrol has recently been discovered to eradicate acute myelogenous leukemia stem 
cells through simultaneous inhibition of NF-κ B-mediated survival signals and induction of 
oxidative stress. It is therefore possible that when compared to other HSP90 inhibitors 
celastrol possesses unique anti-tumor properties.(Peng et al., 2011). 
 
 
 
2.3 Combinational Hybrid Theory 
 
The concept of “hybrid drugs” has been gaining popularity in medicine. Since a single drug is 
not always able to adequately control the illness, the combination of drugs with different 
pharmacotherapeutic profile may be needed .Drugs involving the incorporation of two drug 
pharmacophores in a single molecule with the intention of exerting dual drug action have 
been described . For example, one of the hybrid parts may be incorporated to counterbalance 
the known side effects associated with the other hybrid part, or to amplify its effects through 
action on another biological target. Ultimately, no matter how familiar the building blocks 
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may be, hybrid drug molecules may, at their core, become new molecules with identities 
independent of their precursors.  
 
Hybrid molecules with dual functionality development and/or multitherapeutic strategies, 
which utilize new chemical entities with two (or more) different heterocyclic skeletons 
(pharmacophores), represent a valid and rational approach in design and development of 
novel Hsp 90 inhibitors. These drugs have the potential to surmount the rapid development of 
resistance, enhance patient compliance, and reduce both the cost and the risk of drug–drug 
interactions.( Muregi et al, 2012). Blagg and coworkers  reported the design synthesis and 
biological evaluation  of some chimeric compounds bearing both the quinone moiety present 
in geldanamycin  and resorcinol groups present in radicicol; the new hybrid compounds 
proved to be endowed with better binding affinity and improved inhibitory activity against 
cancer. More recently, Walsh and coworkers2 combined fast-acting artemisinin and slow-
acting quinine into a hybrid drug for malaria, for which drug resistance is a barrier to 
effective treatment. In vitro assays showed that the hybrid is more effective against drug-
sensitive and drug-resistant malaria than the individual drugs alone or a cocktail made of a 
1:1 molar ratio of the two. Walsh suggested that the hybrid drug may increase cellular uptake 
which improves the treatment's efficacy, Vangapandu and co-workers  demonstrated that 8-
quinolineamines conjugates as well as their “double prodrugs” had promising in vivo activity 
in mice. If these compounds, in which basic pharmacophore 4is primaquine, are modified to 
improve their blood schizontocide activity, they have the potential to be used as broad-
spectrum (tissue and blood schizontocides) antimalarial agents.  
Conjugation of drugs may, therefore, serve as a useful tool to improve drug solubility and 
stability, and prolong drug release, reduce doses, dosing intervals, and drug toxicity, as well 
as to achieve targetability (Saadeh et al., 2013). 
However, based on the wide interest in the hybrid molecules as well as numerous 
encouraging efficacy and toxicity reports, the next generation of Hsp 90 inhibitor may as well 
be hybrid drugs as opposed to multi-component ones. There are numerous advantages of 
employing hybrid molecules over multicomponent drugs in cancer therapy. Compared to the 
latter, hybrid drugs may be less expensive since, in principle, the risks and costs involved 
may not be different from any other single entity. Another advantage is that of the lower risk 
of drug–drug adverse interactions compared to multicomponent drugs. The downside, 
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however, is that it is more difficult to adjust the ratio of activities at the different targets 
(Morphy et al., 2005). Different types of hybrid molecules could be classified as :- 
1. Conjugates In which the molecular frameworks, that contain the pharmacophores for each 
target are separated by a distinct linker group that is not found in either of the individual 
drugs. Most conjugates contain a metabolically stable linker (Morphy et al., 2005). 
2. Cleavage conjugates have a linker 1designed to be metabolized to release the two drugs 
that interact independently with each target. 
3. Fused hybrid molecules have the size of the linker decreased such that the framework of 
the pharmacophores is essentially touching. 
4. Merged hybrids have their frameworks merged by taking advantage of commonalities in 
the structures of the starting compounds, which give rise to smaller and simpler molecules 
(Morphy et.al, 2005). 
5. Drug-delivery system: As the search for novel7drugs continues, more drugs with novel 
targets are being developed, but many of these do not reach clinical trials due to 
associated toxicity. Hybrid molecules are essentially prodrugs that aid in improving the 
efficacy and reducing the toxicity and other adverse effects of drugs by controlling their 
pharmacokinetic properties (Vangapandu et al., 2003). 
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3. Tools and methodology 
3.1 Various databases, tools and software’s used in research 
1. RCSB-PDB (www.rcsb.org) 
2. Pubmed NCBI (www.ncbi.nlm.nih.gov/pubmed) 
3. Uniprot (www.uniprot.org) 
4. BLAST 
5. Clustal W 
6. Phyre server 
7. Open babel software 2.3.1 
8. PRODRG 2.5 server(beta)  
9. Chemsketch tool provided by ACD Labs 
10.  Chimera visualization tool 
11.  Docking  tool:- Glide (Schrodinger software, Maestro 9.6) 
12.  ADMET prediction tool:- Qik Prop (Schrodinger software, Maestro 9.6)(Kind gift 
from  Raghu Rangaswamy, Executive Director, Schrodinger, www.Schrodinger.Com, 
Innovations In Computational Chemistry, Bangluru). 
 
3.2 Extraction of protein sequence from UNIPROT 
 
UniProt is a comprehensive, high quality and freely accessible database of protein sequence 
and functional information, many entries being derived from genome sequencing projects. It 
contains a large amount of information about the biological function of proteins derived from 
the research literature. The UniProt consortium comprises the European Bioinformatics 
Institute (EBI), the Swiss Institute of Bioinformatics (SIB), and the Protein Information 
Resource(PIR). Its URL address is (www.uniprot.org). 
 
1. The above mentioned URL was browsed.  
2. In search option, Hsp90 alpha was typed.  
3. There were many results of the search but the human species type of Hsp 90 alpha of 
isoform 2 was selected and its fasta sequence was selected.  
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               Figure 2 : Fasta protein sequence selected from uniprot for Hsp 90 modelling. 
 
3.3 Hsp 90 protein modelling from Phyre server 
 
PHYRE is an automatic fold recognition server  used for calculating the structure and 
function of the protein sequence which has been entered in the serverx. It works on the 
principle of Homology Modeling and based on Hidden Markov Models. It is basics primarily 
used only for academic purpose. 
 
1. Phyre server webpage was browsed with link address (www.sbg.bio.ic.ac.uk/phyre2) 
2. E-mail id and project title is submitted. 
3. Fasta sequence of the protein if pasted and the job is allowed to run for approximately 5 
hrs and results are send to email. 
 
 
 
21 
 
 
 
Figure 3:- Webpage of phyre server showing paradigm of modelling enquiries. 
 
 
Figure 4:- Full Hsp 90 modelled protein from phyre server 
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3.4. Retreival of ligands from pubchem database 
Pubchem is a free access database containing chemical and structural information of small 
organic substances, bioassays, patents as well as provide knowledge about their biological 
activity and cross refer it from original  and related structures. PubChem is 3organized as 
three linked databases within the NCBI's Entrez information retrieval system. 
1. Pubchem with url address https://pubchem.ncbi.nlm.nih.gov/ is browsed. 
2. Specific names of Hsp 90 inhibitors are searched. 
3. Then specific selection of the type of compound and download the 3D structure of 
compound  in .sdf format.  
3.5 Conversion of format of ligand from .sdf to pdb format by using OPEN BABEL  
Download Open babel software from internet. 
1. The input format was selected as .sdf and the file was browsed from its specific location. 
2. The output format of the file was selected as .pdb and convert button was pressed. 
3. The output files were generated and saved in the selected folder in .pdb format.  
 
3.6 Designing of hybrid compounds by using Chemsketch  
ACD/ChemSketch freeware  is a chemically intelligent drawing interface that allows to draw 
almost any chemical structure including organics, organometallics, polymers, and Markush 
structures.  Draw and view structures in 2D, or render in 3D to view from any angle. It also 
generate structures from InChI and SMILES strings and7IUPAC systematic names for 
molecules of up to 50 atoms and 3 ring structures. Search for structures in the built-in 
dictionary of over 165,000 systematic, trivial, and trade names. It also includes features such 
as calculation of molecular properties (e.g., molecular weight, density, molar refractivity 
etc.), 2D and 3D structure cleaning and viewing, functionality for naming structures (fewer 
than 50 atoms and 3 rings), and prediction of logP. 
 
For designing of the hybrid structures, first their structural related chemical properties were 
studied and then the functional groups of the every drug was taken into account  and hybrid 
 
 
23 
 
drug was made  based on the scaffold of the existing drugs structure. For designing of the 
structure we have taken into consideration  various bonds and functional groups based on 
their respective property to be laid on to increase the effectiveness of the drug like integration 
of polar groups like alcohol, amine, amide, carboxylic acid, oxyacid 7groups which would 
either ionize or are capable of relatively intermolecular force of attraction and changing the 
number of methylene groups simulteaneoulsy there leads to increase in lipophilicity or 
decrease of water solubility and so is the change in degree of unsaturation brings change in 
rigidity, sensitivity and toxicity. Introductions of groups like halogens and hydroxyl groups 
would lead to binding site characterization of hydrophilicity character so would lead to 
change in bonds stability and reactivity of the molecule. Bonds like ester,2 amide, phosphate 
and glycosidic bonds bring liability of easy metabolization from various enzymes and lipases. 
 
1. Open ACD/chemsketch software. 
2. Import the chemical 2D structure of dimer of Hsp90 inhibitors. 
3. Amalgamate two structures by using linker group in between them which could be 
either any alkyl or acyl bond or could be bond containing ester, amide, phosphate, 
sulphate or glycosidic groups and further to add or to decrease the properties of the 
complex either hydrophilic or hydrophobic groups could also be added like apolar 
groups methyl, acyl and polar groups hydroxyl, halogens respectively. 
4. Save the file in .sdf format . 
 
3.7 Docking by using Glide 6.2 tool of Schrodinger software 
 
Protein Preparation:- 
 
Protein preparation wizard of maestro 9.6 consist of 3 steps for preparation of protein 
 
1. Preprocessing:- Assigning bond orders, adding hydrogen, creating disulphide bonds, 
deleting  water molecules  
 
2. Review and modifying:- After ensuring chemical correctness, hydrogen was added where 
hydrogen atoms were missing. Side chains that are not close to 
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the binding cavity and do not participate in salt bridges were 
neutralized group.  
 
3. Refining:- Bond orders and ionization states are properly assigned and performs better 
when side chains are reoriented when necessary and steric clashes are relieved. 
The hydrogen bonding network was optimized by reorienting hydroxyl groups, 
water molecules, and amide groups of Asn and Gln, and selecting appropriate 
states and orientations of the imidazole ring in His residues.  
 
Optimizing the orientation of the various groups is an iterative process, which passes over all 
the groups whose H-bonds need to be optimized multiple times. The refinement component 
performs a restrained impact minimization of the co-crystallized complex. This helps in 
reorientation of side-chain hydroxyl It uses the OPLS-AA force field (Jorgensen et al., 1996) 
for this purpose. 
 
1. Import complete protein structure of Hsp 90 consisting of all three domains is prepared 
from phyre server after taking the fasta sequence from uniprot database. 
2. Preprocess the protein structures and remove nonessential water molecules and other ions 
present in it. 
3. Review and modify to check if there is any task undone needed for preprocessing. 
4. Finally refine the protein structure by optimizing and then minimizing the restrained 
structure of Hsp 90. 
 
 
3.7.2   Active site prediction 
 
To explore the active sites in our selected PDB complex , we have made protein  underwent 
Site map program which generated sufficient information4describing the binding site 
novelties ,it identifies the site by use of grid points and then the contour maps are generated 
producing the hydrophobic and hydrophilic maps and later accessment of each site is done by 
calculating various site  points ,site size, enclosure and exposure etc and the best binding site 
is selected with average SiteScore around 1.0. 
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3.7.3 Ligand preparation 
 
Then these structural formations are assigned an appropriate bond order and optimized in 
OPLS force field using a default setting (Hayes et al., 2004) using the ligprep script shipped 
by Schrodinger and finally minimized  it low and stabilized  energy in 3D format. 
 
The LigPrep process consists of a series of steps that perform conversions, apply corrections 
to the structures, generate variations on the structures, eliminate unwanted structures, and 
optimize the structures. The simplest use of LigPrep produces a single low-energy 3D 
structure with correct chiralities for each successfully processed input structure and can also 
produce a number of structures from each input structure with various ionization states. 
 
1.  Import all the hybrid molecules in the project table provided in workspace of maestro 
wizard. 
2.  Open ligprep script shipped by Schrodinger and browse the selected entries of the ligands. 
3.  OPLS force field generated ligands were created. 
 
3.7.4    Receptor grid generation 
 
For receptors that adopt more than one conformation on binding, it is necessary to prepare 
grids for each conformation to ensure that possible actives are not missed. Grid files represent 
physical properties of a volume of the receptor (specifically the active site) that are searched 
when attempting to dock a ligand. Also the shape and properties of the receptor are 
represented on a grid by several different sets of fields that provide progressively more 
accurate scoring of the ligand poses. Grids were generated by Receptor Grid Generation 
panel which defines receptor structure by excluding any co-crystallized ligand that may be 
present, determines the position and size of the active site as it will be represented by receptor 
grids, and sets up Glide constraints. Grids were defined by centering them on the ligand in the 
crystal structure using the default box size. 
1.  Open receptor grid panel of glide  
2.  Define the receptor present in workspace 
3.  Scaling of charge and per atom vander walls radii. 
4.  Define the grid scaling for providing the binding site to attach the ligand 
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5.  Allow the formation of grid cage near the active site after running the job. 
 
3.7.5    GLIDE docking of inhibitors and ligands 
 
Docking refers to the computational investigation for optimal positioning of a ligand 
molecule with respect to the binding site of a target structure. We used the docking program GLIDE 
from Schrodinger which evolves the full span of speed and accuracy from high-throughput 
virtual screening of several compounds. Docking studies were performed of various designed 
hybrid drugs on most eminent N-Terminal domain of Hsp90 as it contains the principal ATP-
binding site of the chaperone and shows a two-layer sandwich fold thus providing preferable 
strong binding pocket to the ligands. For interaction of protein and ligand we have used 
modelled full Hsp90 protein from phyre server. In glide software they have used OPLSAA 
algorithm which approximates a systematic search of positions, orientations, and 
conformations of the ligand in the receptor binding pocket using a series of hierarchical 
filters. XP method is preferred as it weeds out false positives and provide a better correlation 
between good poses and good scores. Glide Score XP specifically priortizes occupancy of 
well-defined hydrophobic pockets by hydrophobic ligand groups and also improvizes  the 
scoring of hydrogen bonds as well as detection of buried polar groups and provide 
accessibility to detection of pi-cation and pi-pi stacking interactions. The XP paradigm for 
flexible docking includes ligand flexibility in the provided grid box of 50 Å. In flexible 
docking ligand is centralised at the midpoint between the two most widely separated atoms of 
the core region of Hsp 90. All 28 ligands were flexible docked with negative XP G Score and 
the compounds were ranked by the interaction energy. 
 
1. Select the receptor file present in .mae format and specify the type of docking mode to be 
carried out (XP,SP etc.) 
2. Select the file of all ligands which was prepared by using ligprep also present in .mae 
format. 
3. Start docking program after providing the job name. 
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3.7.6 Ligand interaction analyses to interpret the residues and bonds involved in 
binding at the binding site 
 
1. Select the docked protein and the specific ligand. 
2. Press the ligand interaction icon present in the tool bar of Maestro wizard 9.6. 
3. Analyse the interaction of protein residues with ligand molecules as well as the bonds 
integrating with it like hydrogen, hydrophobic bond, covalent bond etc. 
 
3.8 ADMET /TOX prediction by using Qikprop3.9 script of Schrodinger software  
 
QikProp is a quick, accurate, easy-to-use absorption, distribution, metabolism, and excretion 
(ADME) prediction program. QikProp predicts physically significant descriptors and 
pharmaceutically relevant properties of organic molecules, either individually or in batches. 
In addition to predicting molecular properties, QikProp provides ranges for comparing a 
particular molecule’s properties with those of 95% of known drugs. QikProp also flags 28 
types of reactive functional groups that may cause false positives in high-throughput 
screening (HTS)5 assays. It also evaluates the acceptability of analogs 6based on Lipinski’s 
rule of five (Lipinski et al., 2001., Lipinski et al., 1997), which is essential to ensure drug-like 
pharmacokinetic profile while using rational drug design. All the analogs were neutralized 
before being used by Qikprop. 
 
The preferable properties which were taken into consideration for evaluation of the process:- 
 
1.   Molecular weight (mol_MW) for better 7drug likeliness its value must be under  
      (150–  650). 
2. Octanol/water partition coefficient (Log Po/w) which denotes for hydrophilicity of both 
compounds. It has been suggested that high log P value is associated with 
poor6absorption or permeation and it must be within the range of (-2–6.5). 
 
3. Aqueous solubility (QPlogS) which significantly affects its absorption and distribution 
characteristics. The predicted log S values of the studied compounds were within the 
acceptable limit of (-6.5–0.5). 
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4.   Apparent MDCK cell permeability (QPPMDCK) is the parameters which mimics the 
blood brain barrier mandatory for inhibition of cancer their value within 25 depicts poor 
property where as greater than 500shows elevated property. 
 
5.   Brain/blood partition coefficient (QPlogBB) is referred in 8order to denote the ability of 
drug to effectively permeate the drug blood brain barrier and could be orally delivered, 
therefore their range should be within (-3.0–1.2). 
 
6.    Percent human oral absorption (C80% is high, B25%is poor) 
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4. Results and Discussion 
 
4.1 Site map of Hsp 90 
 
The location of the primary binding site on a receptor such as a protein is often known from 
the structure of a co-crystallized complex. Efforts to design better ligands for these receptors 
can profit from an understanding of how well the known ligands complement the receptor, 
and how extension of the ligands into adjacent regions could promote binding. site maps 
explicitly show the shape and extent of phillic and phobic regions, something a surface-based 
display cannot do. The most important property generated by SiteMap is an overall SiteScore, 
which has proven to be effective at identifying known binding sites in co-crystallized 
complexes. As it could be retrieved from the results that site 3 and 4 showed highest site 
score with highest hydrophobic cavity thus is viable site for finding active site residue as well 
as binding other hydrophobic residue. Sites 2 and 5 having site score greater than .08 are 
capable of distinguishing between drug binding and non drug binding site. Similarly like site 
score, D score which represent the druggability score which distinguishing “difficult” and 
“undruggable” targets from “druggable” ones. 
 
Table 1:- Different binding sites been searched in full Hsp 90 modelled protein  
     by “Site map” script of  Schrodinger.        
 
No. of 
site map 
Site 
score 
Size Dscore Volume Contact Phobic Phillic 
Site 
map 3 
1.084 
 
298 
 
1.09567 
 
661.647 
 
1.07369 
 
1.156128 
 
1.034849 
 
Site 
map 4 
1.037 129 1.058623 293.608 1.028453 1.307783 1.007047 
Site 
map 1 
1.021 412 0.998315 995.043 0.936868 0.506368 1.164753 
Site 
map 2 
0.989 370 0.946359 
1081.13
6 
0.918335 0.431626 1.236666 
 
Site 
map5 
0.96541
3 
107 0.985962 262.738 0.920571 0.329739 1.048487 
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Figure 5:- Site map 3 remarking various nature of residues as under specific property 
regions (yellow region-hydrophobic, red-hydrohillic and blue-hydrogen bond donor, 
green-hydrogen bond acceptor). 
 
Later at site 3, from hydrophobic area amino acid residue ASN 51 and Lys 112 are selected 
as they are also mentioned in binding site residue in uniprot database of Hsp 90 protein 
selected from human species. 
 
4.1 Hydrophobic and Hydrophillic site mapping of Hsp 90 
 
4.2  
 
 
 
 
Figure 6:- Depiction of hydrophobhic and hydrophilic map surrounding the resotchol   
inhibitor. 
Van-der Waals and distance-dependent electrostatic-interactions of a probe placed at each of 
the grid points are then used to generate van-der Waals and electric-field grids. The resultant 
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van-der Waals and electric-field grids are then used to generate the phobic and philic 
potentials. Red region is showing phobic region and white region are showing hydrophilic 
region , Hydrophobic regions that are favourable for occupancy by hydrophobic ligand 
groups, hydrophilic regions that are favourable for occupancy by hydrophilic ligand groups 
and neither hydrophobic nor hydrophilic—regions that are of mixed character or are far 
enough from the receptor surface to be similar to bulk water. 
4.3 Hybrid structures formed by chemsketch software 
 
Designing of hybrid structures was based on scaffold of existing drug structures, drug like   
geldanamycin  which was most primiarly drug to inhibit Hsp 90 expression by binding at 
amino terminal of Hsp 90 by means of ATPase but is also also associated with various 
demerits like hepatotoxicity, low solubility etc. Although it various analogues have been 
prepared which has also reached to trial phase but with no successful solution on the contrary 
radicicol which is also N terminal binding as much greater affinity for binding then 
geldanamycin and invitro also found to have greater inhibitory activity then GA. Structural 
Basis for Inhibition of the Hsp90 Molecular Chaperone by the Antitumor Antibiotics 
Radicicol and Geldanamycin. 
 
So when chimera complex was formed containing the resorcinol entity of radicicol and 
quinone entity of geldanamycin, joined by varied linker group and at various sites of drugs 
.The various compounds which were formed are like H7 are joined by amide linker group, 
H12 by ester linkage and compounds like H16 are macrocyclic entities. After molecular 
docking they were concluded to have better binding affinity as they are composed of additive 
properties of two natural drugs and thus enhanced potency and affinity (Shen et al., 2009). 
 
On the same ground of concepts hybrids of other drugs like radicicol nd PU3 are formed 
which are again desired to have better affinity and combined properties of two drugs.As we 
are aware of the fact that Hsp 90 ATP binding pocket contains both hydrophobic and 
hydrophilic pocket ( eong et al.,  2014).With ligand interaction it was revealed that, and 
radicicol a containing resorcinol group is entities  exposed towards the solvent and polar 
groups like Thr109, Asn 106, Asn 51  where as PU3 functional entity was facing towards 
hydrophobic residues like Phe 138, Met 96 , Ala 55 etc. So this interaction and amalgamation 
of functional entities of existing drugs has strengthened our envision of better effective 
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inhibition of Hsp 90. With respect to other perks achieved from hybrid theory they have also 
deduced to have preferential admet properties also which make them more susceptible 
towards cancer therapy. 
 
Other significant complexes were formed like between N-Terminal and C-Terminal drugs , as 
they provide more flexibility towards two binding sites and thus more embarked inhibition of 
Hsp 90. Novobiocin belonging from the class of flavonoids contains pyrazole rings having 3-
dimethylally l-4-hydroxybenzoyl moiety (ring A),7a 3-amino-4,7-dihydroxycoumarin moiety 
(ring B). This compound scaffold is when merged with functional groups of other drugs like 
quinone group of geldanamycin, resorcinol group of radicicol or chalcone group, then they 
exhibit improved and cumulative properties of both drugs as aminocoumarin entity is 
flanging away from the active site and the group near the bonding site is that of resorcinol or 
quinone as they are covered with many hydrophobic residues as well as showing more 
intimacies with area near the active residue (Cruz et al., 2010). 
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Table 2:- Illustration of  structures of existing Hsp 90 inhibitors and from them formed 
hybrid structures and their respective affinity towards particular terminal. 
 
S.No. Drug 1 Affinity 
Toward
s Site 
Drug 2 Affinity 
Towards 
Site 
Hybrid Structure Affinity 
towards 
the ATP 
binding 
site 
1. EGCG 
 
 
 
CTD RADICICOL 
 
 
NTD (RAD-EGCG1)(H1) 
 
NTD 
2. EGCG 
 
CTD RADICICOL 
 
NTD  (RAD-EGCG)(H2) 
 
 
NTD 
 
3. 
 
DERRUBONE 
 
 
CTD 
 
EGCG 
 
 
CTD 
 
 (DERR-EGCG)(H3) 
 
 
 
 
NTD 
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4. RADICICOL 
 
NTD DERRUBONE 
 
CTD  (DERR-RAD1)(H4) 
 
NTD 
  5.   RADICICOL 
 
    NTD CELASTROL 
 
   CTD  (RAD-CEL)(H5) 
 
 
NTD  
6. 17DMAG 
 
NTD MONOCILIN 
 
NTD  (17DMAG-MONO)       
(H6) 
 
 
NTD 
 
7. 
 
GELDANAMY
CIN 
 
 
 
NTD 
 
RADICICOL 
 
 
NTD 
 
 (GEL-RAD)(H7) 
 
 
NTD  
8. RADICICOL NTD GELDANAMY
CIN 
NTD (RAD-GEL1)(H8) NTD 
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9. RADICICOL 
 
NTD GELDANAMY
CIN 
 
NTD  (RAD-GEL 2)(H9) 
 
NTD  
10. DOXORUBICI
N 
 
CTD GANATESPIB 
 
NTD  (DOX-GAN) (H10)
 
 
NTD 
11. RADICICOL 
 
 
 
 
 
 
NTD 17AAG 
 
 
 
NTD  (RAD-17AAG)(H11) 
 
 
 
NTD 
12. RADICICOL NTD GELDANAMY
CIN
NTD  (RAD-GEL2)(H12) NTD  
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13. NOVOBIOCIN 
 
CTD GELDANAMY
CIN 
 
NTD (NOV-GEL)(H13) 
 
NTD 
14. NOVOBIOCIN 
 
   CTD RADICICOL 
 
NTD (NOV-RAD)(H14) 
 
 
NTD 
15. GELDANAMY
CIN 
 
 
 
NTD PU3 
 
NTD 
 
GEL-PU3 (H15) 
 
NTD 
16. GELDANAMY
CIN 
 
NTD RADICICOL 
 
 
NTD  (RAD-GEL3)(H16) 
 
 
NTD 
17. DERRUBONE CTD PU3 NTD PU3ISOFLAVO(PU3-
DERRU)(H17) 
NTD 
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18. VER49009 
 
NTD PU3 
 
NTD  (PU3-VER)(H18)
 
NTD 
19. RADICICOL 
 
NTD DERRUBONE 
 
CTD (DERR-RAD 2)(H19) 
 
NTD 
20. RADICICOL 
 
NTD DERRUBONE 
 
CTD  (DERR-RAD3)(H20) 
 
NTD 
21. RADICICOL 
 
 
NTD 17AAG 
 
NTD  (RAD-17AAG(H21) 
 
NTD 
 
22. 
 
RADICICOL 
 
NTD 
 
GELDANAMY
CIN 
 
NTD 
 
 (RAD-GEL)(H22) 
 
NTD 
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23. RADICICOL 
 
NTD GELDANAMY
CIN 
 
 
 
NTD  (RAD-GEL 2)(H23) 
 
NTD 
24. DOXORUBICI
N 
 
CTD GANATESPIB 
 
NTD  (DOX-GAN)(H24) 
 
NTD 
25. DOXORUBICI
N
 
CTD GANATESPIB 
 
NTD  (DOX-GAN(H25)
 
NTD 
26. EGCG 
 
 
 
 
 
 
 
CTD RADICICOL 
 
 
NTD (RAD-EGCG(H26) 
 
NTD 
27. EGCG CTD RADICICOL NTD  (RAD-EGCG 4) (H27) NTD 
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Figure 7:- Ligand interaction diagram showing the interaction of different functional 
group with amino acid residues of Hsp 90. 
Similarly other chimeric compounds were formed containing isoflavone group  and catechin 
group from flavanoids which are the obtained natural from natural source like green tea, 
grapes, blue berries etc they are the source of pharmaceutical potentials like anti-allergic, 
 
 
 
28. VER-49009 
 
NTD RADICICOL 
 
NTD (VER-RAD1) (H28) 
 
NTD 
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anti-inflammatory, antioxidant, anti-microbial (antibacterial, antifungal and antiviral), anti-
cancer, and anti-diarrheal activities, and led to formation of hybrid with highly  potentiated 
qualities. Anthracycline inhibitors like doxorubicin,6epirubicin containing polyketide chain 
though they are successful CTD Hsp 90 inhibitors but again they are associated with severe 
 
side effects like drug induced heart failure,2neutropenia, leukopenia, hand and foot syndrome 
etc which restrict their isolated usage. So combining its structure with enhanced quanlity 
natural drugs can serve as better option for cancer therapy. 
 
 
4.4 Docking of hybrid drugs at both domains of Hsp 90  
 
Table 4: Table depicting binding affinity of various existing drugs derived from 
Glide (Schrodinger software 
Hsp0 inhibitor Binding affinity at NTD 
(Docking score) 
Binding affinity at CTD 
(Docking score) 
EGCG -8.420 -6.556 
Derrubone -8.133 -4.191 
Doxorubicin -7.919 -6.542 
Novobiocin -6.620 -5.228 
Radicicol -5.740 -4.134 
Celastrol -5.132 -5.06 
Ganatespib -5.172 -3.052 
Epirubicin -6.564 -5.191 
Geldanamycin -5.175 -5.393 
PU 3 -4.699 -3.133 
17dmag -5.578 -5.478 
17aag -5.892 -5.745 
Monocillin -5.689 -4.854 
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Table 5:- Respective hybrid compound drugs and their source existing inhibitors with 
                 their affinity towards specific domain of Hsp90 
S.N
o. 
Name 
Docking 
Score at 
ASN 51 
(NTD) 
Glide 
Score 
Docking score 
at LYS 112 
(NTD) 
Docking score at 
Lys 632 (CTD) 
Prime 
MGBSA δ 
BIND 
1.  (H1) -7.946 -7.946 -10.115 
 
-3.814 
 
-62.552 
 
2. 1YET 
ligand 
-7.894 -7.894 -9.457 -5.342 -95.987 
3.  (H2) -7.559 -7.583 8.99597 -3.224 -69.352 
4.  (H3) -7.450 
 
-7.450 
 
8.8854 -2.874 -72.306 
5.  (H4) -6.862 -6.863 
 
8.66995 -2.478 -69.307 
6.  (H5) -6.687 -6.694 7.96083 -2.845 -44.323 
7. (H6) -6.794 -6.847 7.55376 
 
-3.378 
 
66.228 
8.  (H7) -6.613 -6.905 7.37712 
 
-4.166 
 
60.823 
9.  (H8) -6.420 -6.451 6.8989 
 
-3.618 
 
58.923 
10 (H19) 6.453 -6.454 6.76364 -3.654 
   
73.23 
 
11  (H22) -6.335 -6.640 6.39227 
-3.779 
 
-73.330 
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12  (H9) -6.341 -6.558 6.23161 
 
-4.60892 
 
-76.581 
13  (H23) -6.081 -7.339 6.10123 
 
-4.30851 
 
-65.780 
14  (H24) -6.300 -6.389 6.0312 
 
-4.25435 
 
63.3307 
15  (H21) -6.136 -6.178 6.00353 
 
-3.37114 
 
53.0832 
16  (H25) -6.088 -7.880 5.94137 
 
-4.09472 
 
76.3303 
17  (H10) -5.870 -5.960 5.91688 
 
-3.89678 
 
50.4574 
18  (H17) -5.805 -6.174 -5.689 
 
-2.78604 
 
64.6302 
19 (H20) 5.744 -5.745 
 
-5.819 -2.568 -68.958 
20  (H12) 5.565 5.725 5.82252 -2.487 -65.594 
21  (H26) -5.080 -5.103 5.81752 
 
-2.92873 
 
-50.934 
22  (H13) -5.074 -5.577 5.21148 -2.5364 -81.267 
23  (H14) -4.886 -5.206 -5.07334 -2.30372 -49.533 
24  (H15) -4.604 -4.902 
 
-3.247 -5.697 -82.722 
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Table 6:Final representation of promising hybrid drugs having better binding affinity 
from their derived drugs. 
 
In all the drugs, H1 showed highest binding affinity as its hydroxyl groups are attached with 
charged negative Asp 102 by hydrogen bonding and hydroxyl groups are interacting with 
charged positive Lys 116 bonded with hydrogen bonding in the hydrophobic vicinity of HSP 
90.Additionally this group is also surrounded by polar Glu 133, Asn 51,Leu 96,Ala 55 and 
Met 98 providing it the hydrophillic arena. 
 
25 (H16) -4.553 4.566 -3.854 
 
-4.20606 
 
-26.530 
26 (H11) 3.033 -3.034 -4.086 -2.369 -74.532 
27 (H17) 1.834 -2.385 
 
-3.818 
 
 
-3.458 -67.267 
28  (H28) -3.658 -3.658 
 
-3.213 
 
-2.874 51.658 
29  (H27) .0156 -2.255 -3.053          -2.928 -44.982 
Hybrid Drug 
name 
 
Parent Drugs docking score Hybrid drug 
score 
Binding 
site Drug 1 Drug  2 
H1(EGCG-RAD) -8.420 -5.740 -10.115 NTD 
H2(EGCG-RAD) -8.420 -5.740 -8.995 NTD 
H3(EGCG-DOC) -8.420 -7.919 -8.885 NTD 
H4(RAD-DOC) -5.740 -7.919 -8.669 NTD 
H5(CEL-RAD) -5.132 -5.740 -7.960 NTD 
H6(17DMAG-
MONO) 
-5.175 -4.120 -7.553 NTD 
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H1 is hybrid of two functional groups resorcinol and catechin which is derived from natural 
source of green tea leaves and is powerful antioxidant and anticarcinogenic agent  whereas 
resorcinol is derived from resins and is also nice2antiseptic and resorcinol moiety binds in the 
same location as adenine ring of ADP and mimics the hydrogen bond donor /acceptor 
properties of exo and N7 endocyclic amine /imin respectively and when collectively docked 
to Hsp 90 N Terminal domain ,resorcinol moiety showed greater affinity towards the N 
Terminal and got attached near Asn 51 and Lys 112 with catechin group having more 
phillicity towards C Terminal and it was hanging backwards. 
 
The docked poses were then minimized using the local optimization feature in Prime, and the 
energies were calculated using the OPLS-AA force field and the GBSA continuum model in 
Maestro. The binding free energy  ∆ Gbind is estimated as where  ∆ EMM is the difference in 
energy between the complex structure and the sum of the energies of the ligand and 
unliganded protein, using the OPLS force field, ∆ Gsolv is the difference in the GBSA 
solvation energy of the complex and the sum of the solvation energies for the ligand and 
unliganded protein, and  ∆ GSA is the difference in the surface area energy for the complex 
and the sum of the surface area energies for the ligand and uncomplexed protein. 
 
  ∆ Gbind= ∆ EMM +  ∆ Gsolv + ∆ GSA...................................................................(1) 
 
Higher the prime energy better is the values of the stability of the conformer. 
 
4.5 ADMET/TOX  Study 
 
All the structures showed significant values for the properties analyzed (Table 7 ) and showed 
drug-like characteristics based on Lipinski’s rule of 5.The first three properties are based on 
Lipinski rule of five, molecular weight (mol_MW) less than 650, partition coefficient 
between octanol and coefficient between octanol and water (logPo/w) between -2 and 6.5 and 
solubility (QPlogS) greater than -7. Brain/blood partition coefficient (QPlogBB) parameter 
indicated about the ability of the drug to pass through the blood–brain barrier which is 
mandatory for inhibition of cancer. Whereas QPPMDCK predicted apparent MDCK cell 
permeability in nm/s. MDCK cells are considered to be a good mimic for the blood–brain 
barrier. Higher the value of MDCK cell, higher the cell permeability. All designed 
compounds had showed ADME properties in acceptable range. On taking detailed look we 
found that drug H1 showed lowest molecular weight thus low dose uptake and has higher 
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water solubility in reference to geldanamycin, 3similarly its efficiency to cross blood brain 
barrier is also sufficient enough with high percentage of human oral absorption providing it 
more impetus over other drugs as it contains highest binding affinity thus more affirmation in 
inhibiting Hsp 90. In view of other drugs like H2 and H3, these drugs also have 
comparatively similar properties to geldanamycin in context of water solubility, brain 
membrane permeability,oral absorption but due to their greater weight index they are having 
liability of heavier dose thus greater toxicity. 
 
 
Table 7:-Depiction of various admet properties of each hybrid compound. 
 
 
Drug 
Name 
Mol. wt 
(Molecular 
weight) 
QP Log S 
(Solubilit
y 
coefficien
t) 
QP Log 
Po/V(wat
er/octanol 
coefficien
t) 
QP LOG 
BB(Blood 
brain 
barrier 
coefficien
t) 
QPLOGM
MDCK 
(cell 
memebrane 
permeabilit
y 
coefficient) 
%Huma
n 
Absorpti
on 
 (H1)  
  
(H2)  
(H6)  
(H7)  
(H8)  
(H11)  
(H10)  
(H15)  
 (H14)  
 (H15)  
 (H16)  
 (H17)  
 (H13)  
 (H10)  
 (H11)  
 (H20)  
 (H21)  
 (H22)  
 (H28)  
 (H22) 
 (H25) 
 (H4) 
 (H5) 
 (H9) 
 (H18)  
398.36 
 
432.81 
431.44 
413.81 
375.33 
413.81 
409.77 
575.57 
386.36 
575.57 
575.57 
420.80 
413.81 
411.79 
420.80 
432.81 
344.32 
575.57 
432.81 
389.79 
563.39 
488.76 
548.16 
433.24 
415.27 
-3.556 
 
-4.166 
-2.085 
-3.327 
-3.379 
-3.225 
-3.809 
-4.978 
-3.389 
-6.705 
-6.293 
-3.982 
-3.335 
-3.308 
-3.912 
-4.181 
-2.737 
-6.52 
-4.214 
-3.77 
-8.157 
-6.184 
-6.759 
-4.834 
-6.928 
0.76 
 
1.254 
0.775 
1.08 
0.847 
0.85 
1.104 
2.566 
0.906 
2.648 
3.01 
1.36 
0.832 
1.433 
1.411 
1.217 
0.521 
2.634 
1.251 
1.376 
5.793 
3.794 
4.617 
2.762 
4.68 
-2.903 
 
-2.717 
-2.48 
-2.176 
-2.908 
-2.35 
-2.867 
-3.211 
-3.019 
-4.251 
-3.491 
-2.815 
-2.597 
-2.155 
-2.734 
-2.782 
-1.882 
-4.142 
-2.762 
-2.004 
-0.944 
-1.387 
-1.383 
-1.341 
-0.622 
5.416 
 
14.987 
2.813 
41.864 
7.805 
24.904 
12.61 
4.293 
6.23 
2.075 
6.257 
19.238 
12.968 
40.427 
20.569 
12.829 
31.326 
2.381 
13.898 
25.178 
1042.2 
245.3 
321.05 
192.72 
1490.1 
39.662 
 
43.82 
47.272 
64.685 
55.759 
62.152 
56.645 
22.653 
54.482 
14.468 
27.962 
59.14 
57.232 
66.965 
59.939 
42.439 
63.848 
15.13 
43.212 
61.178 
83.047 
89.507 
85.516 
81.683 
100 
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 (H26) 
 (H29) 
 (H23) 
554.22 
422.86 
 
-7.979 
-5.798 
 
5.914 
3.722 
 
-0.128 
-0.807 
 
9507.9 
454.37 
 
93.952 
100 
 
 
 
Most of drug candidates fail in clinical trials due to poor ADME properties. Thus, an 
important aspect of drug discovery is to avoid compounds not having drug likeliness and 
good ADME property. So to streamline the virtual screening, drug likeliness and ADME 
properties of all the thirty compounds were predicted using QikProp, version 3.4 of 
Schrodinger 2013.Lipinski filter and reactive filter were applied before virtual screening to 
avoid false positive lead molecule using Qik prop script of schrodinger (Meraj et al., 2013). 
Lipinski filter rejected ligands not following Lipinski rule of five and reactive filter rejected 
ligands with reactive functional groups and in case non-violation of rule shoed the value of 
zero. Drug likeliness, log P, log S, molecular weight and toxicity risks may be used to judge the 
compound’s overall potential to qualify a ligand as potential drug candidate.  
               All twenty eight ligands have appropriate logP (octanol/water) value for biological 
efficacy. Each of them had zero Lipinski violation and satisfying pharmacological properties of 
95% available drugs with high to medium predicted oral absorption availability. Molecular 
weight of most of the ligand falls within the range of 297-404 Daltons. The ligands are having no 
toxic functional groups. Log S values of these ligands are within the acceptable range of 95% 
of existing drugs. The overall pharmacological properties of these ligands justify that the 
molecules are biologically active without any toxic functional groups. Hydrophobic 
compounds have relatively poor solubility, high log P, and high serum protein binding, but 
good cell permeability; whereas the opposite is true for hydrophilic compounds.  
 
This dichotomy was responsible for the classic lead optimization struggle of solubility versus 
permeability. Poor oral availability and permeability may lead to drug failure. The four lead 
molecules like H1,H2 and H3 reported in the present study are well within the hydrophobic 
and hydrophilic extremes at the same time percentage of oral availability is also high. 
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Figure 8:- Plot of ligand (resotchol) interaction with HSP 90(Ligand interaction tool,  
Maestro 9.6,Schrodinger) 
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4.5 Molecular surface representation of Hsp90 bonded with ligand 
 
Figure 9:- This figure shows cavity inside the receptor molecule for perfect fitting of the 
ligand molecule into the Hsp 90 protein structure (Schrodinger,Maestro 9.6). 
 
 
 
 
 
 
 
 
 
Figure 10:-Picture depicting the pocket of Hsp 90 grasping resotichol (Description:-
Surface molecular mesh created for the particular ligand to represent the part of 
surface volume participating of Hsp 90 protein in docking with the desired ligand). 
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------------------------------------- 
CHAPTER 5 
------------------------------------- 
 
 
Conclusion and Future 
Prospectives 
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5.1. Conclusion  
 
Protein ligand interaction is one of the major mechanisms controlling various paradigms of 
signalling and stabilization networking. Heat shock protein 90 is rational target and   
important molecular chaperone protein having essentiality in stabilization for continued 
function of overexpressed, hybrid or multiple mutated proteins which could turn out to be 
carcinogenic. To inhibit its normal functioning it is made to interact with inhibitors whose 
effectiveness depends on their binding affinity with Hsp 90 protein. We have hypothesized 
new avenue in field of Hsp 90 inhibitors by designing hybrid inhibitors based on the scaffold 
of existing drugs. The basic chemical structures of existing drugs like benzoquinone of 
geldanamycin, resorcinol of radicicol was retrieved and made to ligate with each other by 
using various linker groups. About 30 hybrid structures were designed by using chemsketch 
tool, which were made to undergo stereo chemical stabilization and energy minimization. 
Further to validate their drug ability they were checked by Lipinski rule of five and rule of 
three.  
                  To predict the active site for interaction of ligand ,site mapping tool of 
schrodinger was used which predicted five major site locations in which site 3 was assumed 
to have maximum probability of having most favourable active site as it had highest site 
score of 1.084 and D score of value 1.095. After site prediction, when all hybrid drugs were 
docked to both the domains of Hsp 90, then in N terminal domain, most of hybrid drugs 
secured maximum binding affinity in comparison to C terminal. 
                       After comparative analysis of existing drugs and hybrid drugs on inhibitory 
potential, we have found out that our hybrid drugs attained better glide score. Among 28 
structures which were docked to Hsp 90 protein at active site Lys 112 of N terminal, five 
leading hybrids H1,H2,H3 ,H4 and H5 were selected as they secured maximum glide score  
of 10.115, 9.457, -8.995, 8.885 and 8.669 respectively. We have investigated that in all the 
leading hybrid compounds existing drugs like EGCG, radicicol2 and geldanamycin were 
most common participants in drug designing as well as they also showed individual 
maximum glide score .So it was also concluded that groups like catechin of EGCG 
,resorcinol of geldanamycin and benzoquinone of geldanamycin have most energetically and 
stereochemically favourable interaction with Hsp 90 protein. 
 
                   Further in order to investigate the pharmacological dynamics of hybrid ligands 
and protein, ADMET prediction was done by using Qik Prop tool of Schrodinger. Then it 
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was analysed that drug H1 showed most favourable pharmacological profile with lowest 
molecular weight thus probability of low dose consumption and better QPMDDCK,QP 
logBB value better from their existing drugs ,thus have less chances of side effects and lower 
toxicity values. So in an attempt to find out the amenable hybrid inhibitor by insilico 
methodology, we have investigated that hybrid drugs showed better molecular interaction as 
indicated by glide score and also have probability to show better and satisfying 
pharmacokinetic profile and thus could lead into promising future drug for unveiling the HSP 
90 structure activity relationship and thus combating the dreadful disease of cancer.  
 
 
5.2 Future perspectives 
 
Further in order to explore the pharmacophore profiling and to better understand the structure 
activity relationship, 3D QSAR modelling could be done in order to synchronise the physical 
modelling of protein and its biological activities. Progressively we could also do molecular 
dynamics simulation in order to make most realistic in–vivo model for more assured 
understanding of protein ligand as well as protein–protein interaction.  
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